atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

April 24, 2024

https://www.globenewswire.com/news-release/2024/04/24/2868477/0/en/atai-Life-Sciences-Announces-Dosing-of-First-Patient-in-Part-2-of-Beckley-Psytech-s-Phase-2a-Study-Exploring-BPL-003-Adjunctive-to-SSRIs-in-Patients-with-Treatment-Resistant-Depres.html

NEW YORK and BERLIN, April 24, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ:ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first patient has been dosed in Part 2 of Beckley Psytech’s Phase 2a study, evaluating BPL-003 (intranasal 5-MeO-DMT) in patients living with Treatment Resistant Depression (TRD).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.